Genital Warts Market Report 2026

The genital warts market size has grown strongly in recent years. It will grow from $2.06 billion in 2025 to $2.17 billion in 2026 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to high prevalence of hpv infections, availability of topical drugs, early adoption of ablative procedures, sexual health awareness programs, clinical treatment guidelines.

The genital warts market size is expected to see strong growth in the next few years. It will grow to $2.65 billion in 2030 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to increased hpv vaccination coverage, development of novel topical agents, expansion of outpatient treatments, early screening initiatives, patient preference for non-invasive care. Major trends in the forecast period include rising adoption of topical treatment therapies, increasing awareness of hpv-related infections, growing demand for minimally invasive ablative treatments, expansion of preventive hpv vaccination programs, increased use of home-based treatment options.

The growing prevalence of sexually transmitted infections (STIs) is expected to drive the expansion of the genital warts market in the coming years. Sexually transmitted infections are diseases primarily spread through sexual contact, including vaginal, anal, and oral intercourse, and are caused by bacteria, viruses, or parasites. The incidence of STIs is rising due to factors such as increased sexual activity, inconsistent use of protective measures, and limited access to sexual health education and healthcare services. Genital warts are a common STI caused by certain strains of the human papillomavirus (HPV) and are transmitted through direct skin-to-skin contact during sexual activity. For example, in September 2025, the Centers for Disease Control and Prevention, a US-based public health agency, reported that more than 2.2 million cases of chlamydia, gonorrhea, and syphilis were recorded in 2024. As a result, the increasing burden of sexually transmitted infections is contributing to the growth of the genital warts market.

Key companies operating in the genital warts market are focusing on the development of new treatment options, including innovative dermatology drugs, to address unmet patient needs. Dermatology drugs refer to newly developed pharmaceutical products or therapeutic agents specifically designed to treat skin-related conditions, including genital warts. For instance, in March 2023, Verrica Pharmaceuticals Inc., a US-based dermatology-focused pharmaceutical company, received New Chemical Entity (NCE) designation for its drug candidate YCANTH. YCANTH is under development for the treatment of genital warts and has successfully completed phase 2 clinical trials. With the FDA granting NCE status, the company is entitled to a minimum of five years of protection from generic competition.

In April 2024, Endo, Inc., a US-based generics and specialty-branded pharmaceutical company, completed the acquisition of Endo International plc for an undisclosed sum. Through this transaction, Endo, Inc. seeks to reinforce its portfolio of generic and specialty pharmaceutical products, thereby strengthening its ability to serve both patients and healthcare providers. Endo International plc is a US-based generics and specialty-branded pharmaceutical company.

Major companies operating in the genital warts market are Merck & Co. Inc, Teva Pharmaceutical Industries Ltd, Sun Pharmaceuticals, Perrigo Company plc, Glenmark Pharmaceutical Inc, Taro Pharmaceutical Industries Ltd, ANI Pharmaceuticals Inc, Verrica Pharmaceuticals Inc, CryoConcepts LP, CryoIQ Global AB, Cassiopea Inc, GlaxoSmithKline plc, Pfizer Inc, Bayer AG, Astellas Pharma Inc, Amgen Inc, Boehringer Ingelheim, Johnson & Johnson, Eli Lilly and Company, Novan Inc.

North America was the largest region in the genital warts market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genital warts market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genital warts market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the genital warts market by increasing costs of imported topical medications, ablative devices, and diagnostic supplies. Clinics and hospitals are most affected due to reliance on imported treatment products. These tariffs raise treatment costs by increasing expenses for topical therapies and in-clinic procedures, potentially limiting access in outpatient settings. However, they support domestic drug manufacturing, encouraging local production of topical agents and treatment supplies.

The genital warts market research report is one of a series of new reports that provides genital warts market statistics, including genital warts industry global market size, regional shares, competitors with a genital warts market share, detailed genital warts market segments, market trends and opportunities, and any further data you may need to thrive in the genital warts industry. This genital warts market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Genital warts, also known as condylomata acuminata, are sexually transmitted infections (STIs) caused by specific strains of the human papillomavirus (HPV). They usually appear as small growths or clusters of bumps on or around the genital and anal regions and can vary in size and shape. These warts may be raised or flat and often have a cauliflower-like appearance. While generally painless, genital warts can cause itching, discomfort, or bleeding during sexual activity.

The primary drugs used for treating genital warts include imiquimod, podophyllin, podofilox, and trichloroacetic acid. Imiquimod is a topical cream that works by stimulating the immune system to combat genital warts caused by HPV. The various treatment approaches include chemical treatment, ablative treatment, preventive treatment, and other therapeutic options. These treatments are used for both females and males and are administered across different end users such as hospitals, clinics, and home care settings.

The genital warts market consists of revenues earned by entities by providing services such as medical consultations, diagnostic testing, treatment procedures, follow-up care, and patient education programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The genital warts market also includes sales of topical treatments, cryotherapy devices, surgical instruments, immune response modifiers, and antiviral medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.